HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a $6 price target.
June 26, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cidara Therapeutics (NASDAQ:CDTX) receives a reiterated Buy rating and a maintained $6 price target from HC Wainwright & Co. analyst Ed Arce.
The reiterated Buy rating and maintained $6 price target by HC Wainwright & Co. analyst Ed Arce indicates a positive outlook for Cidara Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100